Skip to search formSkip to main contentSkip to account menu

GSK126

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IndolesPyridones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PKM2-EZH2 INTERACTION ELICITS METABOLIC VULNERABILITY FOR TREATMENT OF TRIPLE- NEGATIVE BREAST CANCER
Triple Negative Breast Cancer (TNBC) is the most aggressive type of breast cancer. TNBC patients are resistant to virtually all… 
2020
2020
IMPROVEMENT OF TREATMENT FOR PROSTATE CANCER AND PLK1’S ROLE IN NON-SMALL-CELL LUNG CARCINOMA
Prostate cancer (PCa) is the second leading cause of cancer related deaths in American men. In this study, I identify two… 
2019
2019
PB1652 ABERRANT EZH2 HIGH EXPRESSION IN THE PATIENTS WITH ACUTE LEUKEMIA AND EFFECT OF A NOVEL EZH2 INHIBITOR GSK126 ON CELL PROLIFERATION AND APOPTOSIS OF THE MALIGNANT CELLS
2018
2018
Investigating novel therapies for Friedreich’s ataxia
Friedreich’s ataxia (FRDA) is a progressive neurodegenerative disorder caused by a homozygous GAA repeat expansion mutation in… 
2016
2016
Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells
Patients with metastatic lung cancer have a very poor prognosis indicating an urgent need to develop more effective chemotherapy… 
2016
2016
EZH 2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells
Enhancer of zeste homolog 2 (EZH2) has been emerged as novel anticancer target. Various EZH2 small-molecule inhibitors have been… 
2014
2014
Combination therapy of the EZH2 inhibitor GSK126 and the PARP inhibitor Olaparib shows in vivo synergy in a patient-derived xenograft model of BRCA1-deficient breast cancer
Background: Current treatment options for BRCA1-deficient breast cancer are limited highlighting the need for novel targeted… 
2014
2014
Treatment of human multiple myeloma cell lines in vitro using EZH2 inhibitors GSK126 and EPZ-6438
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)